Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
Interventions: Plerixafor; Drug
Lead sponsor: Hugh Taylor; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Orange, Connecticut

Conditions: Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Interventions: Adaptive Bridging Radiation Therapy (ABRT); Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: counseling intervention, educational intervention, psychosocial assessment and care; Behavioral · Other · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chevy Chase, Maryland • Hackensack, New Jersey + 1 more

Conditions: Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions: Fecal Microbiota Transplantation Capsule, Placebo; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Macular Degeneration
Interventions: NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks; Drug
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more

Conditions: Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
Interventions: Cemiplimab, Computed Tomography, Biospecimen Collection, Quality-of-Life Assessment, Magnetic Resonance Imaging, Biopsy, Fianlimab; Biological · Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 3
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Tooth Fractures, Tooth Extraction Status Nos, Caries
Interventions: Tooth extraction and ridge preservation using different barrier mermbranes; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vitiligo
Interventions: Needling, Triamcinolone; Procedure · Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 89 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Ebstein Anomaly
Interventions: Autologous Bone Marrow-derived Mononuclear Cells, Insertable cardiac monitor; Biological · Device
Lead sponsor: Timothy J. Nelson; Other
Eligibility: 6 Months to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ovarian, Fallopian Tube and Peritoneal Cancer
Interventions: Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells, SB---485232 (Human recombinant Interleukin---18); Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer, Breast Cancer, Pancreas Cancer, Carcinoembryonic Antigen
Interventions: anti-CEA CAR-T cells; Biological
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Providence, Rhode Island

Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioma, Refractory Glioma, WHO Grade III Glioma
Interventions: HER2(EQ)BBζ/CD19t+ T cells, Laboratory Biomarker Analysis, Leukapheresis; Biological · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
Interventions: filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Immunodeficiency
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years to 40 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: End of Life, Cancer
Interventions: Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care; Other · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 2,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Mobile, Alabama • Duarte, California + 11 more

Conditions: Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
Interventions: CTX0E03 Drug Product and delivery device, Placebo; Combination Product · Drug
Lead sponsor: ReNeuron Limited; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 23
States / cities: Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more

Conditions: Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
Interventions: TROP2-CAR-NK, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Synovial Sarcoma, Soft Tissue Sarcoma, Undifferentiated Sarcoma
Interventions: T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product; Genetic · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2043
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor
Interventions: pH Measurement of in vivo tissue; Diagnostic Test
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Fludarabine, CAR-T Cells; Drug · Biological
Lead sponsor: Benjamin Tomlinson; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 2
States / cities: St Louis, Missouri • Cleveland, Ohio

Conditions: Ulcerative Colitis
Interventions: Remestemcel-L, Placebo; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Photodynamic Therapy (PDT), Verteporfin Injection; Device · Drug
Lead sponsor: SpectraCure AB; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Autologous Hematopoietic Stem Cell Transplant
Interventions: RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
Interventions: CAdVEC; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2038
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions

Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Alveolar Ridge Preservation Following Tooth Extraction.

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma

MT2004-30: Tomotherapy for Solid Tumors

Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Investigation of Neural Stem Cells in Ischemic Stroke

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

Muscle Stimulation for Physical Function During Stem Cell Transplant

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors